Orphan Drug Approvals — October 22, 2026

The FDA approved a label expansion for avapritinib (AYVAKIT) on 2026-10-16, classified as a fallback-type approval with bullish signal at strength 5/10 and materiality 5/10. Indication size, peak sales, and pricing power are NOT_DISCLOSED, so the magnitude of revenue impact cannot be sized.

The source analysis classifies the AVAPRITINIB approval as a fallback type with no disclosed exclusivity, catalyst, or confirmatory-trial detail, leaving the durability and scope of the label expansion unverified.

Expanded AYVAKIT labeling may broaden the addressable patient population for Blueprint Medicines, though the size of that population is NOT_DISCLOSED in the source analysis.

With one approval and no NME, biosimilar, or multi-approval therapeutic area cluster in the period, there is no evidence of a sector-wide theme. The only observation is an isolated bullish label expansion for avapritinib.

{"entity" => "AVAPRITINIB (AYVAKIT) / Blueprint Medicines", "reason" => "Recent label expansion approval on 2026-10-16 with bullish signal, but indication size, sales estimates, and market position are NOT_DISCLOSED, so the commercial impact remains unquantified.", "trigger" => "Blueprint Medicines quarterly earnings disclosure of AYVAKIT revenue and the newly approved indication's launch metrics, or any next PDUFA or confirmatory trial milestone."}